Adagene Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter Luo
- Full Time Employees
- 128
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building C14 Suzhou JS People's Republic of China 215123
- IPO Date
- Feb 9, 2021
- CIK
- 0001818838
- Website
- adagene.com
- Similar Companies
- Business
- Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company that develops novel antibody-based cancer immunotherapies using proprietary technologies including NEObody for targeting unique epitopes with novel mechanisms of action; SAFEbody for precision masking and tumor microenvironment activation to enhance safety; POWERbody for empowered efficacy with local activation; and the Dynamic Precision Library platform integrating computational biology and artificial intelligence. The company focuses on oncology, advancing a pipeline of monoclonal and bispecific antibodies such as ADG106, a CD137/4-1BB agonist for advanced solid tumors and non-Hodgkin's lymphoma; ADG116, a CTLA-4 antagonist enabling Treg depletion and soft ligand blocking; and ADG126 (muzastotug), the lead anti-CTLA-4 SAFEbody in Phase 1b/2 and Phase 2 trials for microsatellite stable colorectal cancer and other solids in combination with anti-PD-1 therapies. Founded in 2011 and headquartered in Suzhou Industrial Park, Jiangsu Province, China, Adagene conducts global research, development and clinical operations with partnerships spanning international organizations. Recent developments include a July 2025 strategic investment and option activation from Sanofi for up to $25 million to fund muzastotug's randomized Phase 2 trial in microsatellite stable colorectal cancer and a third SAFEbody discovery program, extending cash runway into 2027; a November 2025 licensing agreement with Third Arc Bio granting worldwide rights to two masked CD3 T cell engagers using SAFEbody technology for a $5 million upfront payment, up to $840 million in milestones and royalties, while retaining a no-cost option for Greater China, Singapore and South Korea; and a July 2025 partnering agreement with ConjugateBio for novel antibody-drug conjugates.
Company News
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Adagene to Participate in Three Upcoming Investor Conferences
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene to Participate in Two Upcoming Investor Conferences
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Adagene Looks Attractive With ADG126 And Validating Partnerships
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update